This article is more than 5 years old. Information may no longer be current.
Intravitreal anti-VEGF for myopic CNV yields long-term visual gains
Click Here to Manage Email Alerts
Sustained visual gains were observed after a regimen of three monthly intravitreal bevacizumab injections for the treatment of myopic choroidal neovascularization, a study found.
“Both ranibizumab and bevacizumab have produced favorable short-term outcomes in [myopic CNV] without any serious ocular or systemic complications,” the study authors said. “However, in a few recent studies on the 2-year visual outcome of anti-VEGFs, the results are conflicting: visual improvement was maintained in some studies, while others reported a decline.”
The prospective, interventional study included 32 eyes of 30 patients with myopic choroidal neovascularization who underwent three monthly 1.25-mg injections of bevacizumab. All eyes exhibited subfoveal or juxtafoveal CNV, evidence of leakage from CNV, and pathological myopia, defined as spherical equivalent greater than –6 D or axial length greater than 26.5 mm.
All patients were followed up at 2 years; 27 eyes of 26 patients were evaluated at 3 years.
Best corrected visual acuity , CNV area, intraretinal fluid, subretinal fluid and leakage were assessed before and after treatment.
Study results showed that mean baseline BCVA in 14 eyes with juxtafoveal CNV was significantly better than in 18 eyes with subfoveal CNV (P < .0001). Eyes with subfoveal CNV had significantly longer persistence of symptoms (P = .02) and greater CNV (P = .008).
BCVA improved from 30.1 letters at baseline to 45.4 letters at 3 years; the improvement was statistically significant (P < .0001).
Results showed a significant correlation between baseline BCVA and final BCVA (P = .001), and a negative correlation between final BCVA and age (P = .01).
No serious adverse events were reported, the authors said.
Click Here to Manage Email Alerts